Cholecystokinin receptor antagonist, loxiglumide, inhibits invasiveness of human pancreatic cancer cell lines
- 1 April 1996
- journal article
- Published by Wiley in FEBS Letters
- Vol. 383 (3) , 241-244
- https://doi.org/10.1016/0014-5793(96)00245-1
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Effect of the Cholecystokinin Receptor Antagonist Loxiglumide on Pancreatic Exocrine Function in Rats After Acute PancreatitisPancreas, 1995
- 72 KD and 92 KD type IV collagenase, type IV collagen, and laminin mRNAs in breast cancer: a study by in situ hybridization.Journal of Histochemistry & Cytochemistry, 1994
- Cholecystokinin analog, JMV-180, stimulates growth of human pancreatic cancerDigestive Diseases and Sciences, 1994
- Loxiglumide (CR1505), a cholecystokinin antagonist, specifically inhibits the growth of human pancreatic cancer lines xenografted into nude miceCancer, 1993
- Growth Factors and CancerScience, 1991
- Induction and stimulation of 92-kDa gelatinase / type IV collagenase production in osteosarcoma and fibrosarcoma cell lines by tumor necrosis factor αBiochemical and Biophysical Research Communications, 1990
- Pancreatic carcinogenesis-enhancement by cholecystokinin in the hamster-nitrosamine modelBritish Journal of Cancer, 1985
- Exocrine pancreatic tumours and their histological classification. A study based on 167 autopsy and 97 surgical casesHistopathology, 1983
- A HORMONE MECHANISM FOR GALL-BLADDER CONTRACTION AND EVACUATIONAmerican Journal of Physiology-Legacy Content, 1928